Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LEGISLATIVE PHARMACOECONOMIC STANDARD NEED NOT PRECLUDE RIGOROUS STUDIES -- FDA's TEMPLE; DATA BASE ANALYSES ARE NOT SUITABLE FOR COST-EFFECTIVENESS CLAIMS

Executive Summary

The attempt by Congress to set a new legislative standard for FDA oversight of pharmacoeconomic claims should not discourage companies from performing rigorous analyses of their products, Center for Drug Evaluation & Research Associate Director for Medical Policy Robert Temple, MD, told a meeting of the Food & Drug Law Institute Sept. 4 in Washington, D.C.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030797

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel